Scarica l'app Stockscreener
0.88
1.12%
-0.01
Precedente Chiudi:
$0.89
Aprire:
$0.9
Volume 24 ore:
39,619
Relative Volume:
0.05
Capitalizzazione di mercato:
$31.18M
Reddito:
$45.91M
Utile/perdita netta:
$-4.62M
Rapporto P/E:
-6.2767
EPS:
-0.1402
Flusso di cassa netto:
$-21.51M
1 W Prestazione:
-6.35%
1M Prestazione:
+37.48%
6M Prestazione:
+6.96%
1 anno Prestazione:
-64.80%
Intervallo 1D:
$0.86
$0.90
Intervallo di 1 settimana:
$0.85
$0.96
Portata 52W:
$0.493
$3.25
Equillium Inc Stock (EQ) Company Profile
Nome
Equillium Inc
Settore
Industria
Telefono
(858) 412-5302
Indirizzo
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Confronta EQ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.88 | 31.18M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-29 | Ripresa | Stifel | Buy |
| 2021-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
Equillium Inc Borsa (EQ) Ultime notizie
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St
Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World
Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq
Healthy Upside Potential: Equillium Inc (EQ) - SETE News
Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Equillium reports positive Phase 2 ulcerative colitis study data - MSN
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily
What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News
Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily
10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues
UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK
Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance
Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa
Equillium Announces Positive Data from Phase 2 Study Evaluating - GuruFocus.com
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Lugman Group withdraws from purchase of “Industrial Park Fechenheim” - Yahoo Finance UK
Equillium Braces For Two Key Clinical Trial Data ReadoutsWill The Stock Get A Boost? - RTTNews
Equillium CFO Jason Keyes sells $6,500 in stock - MSN
Equillium CFO Jason Keyes sells $6,500 in stock By Investing.com - Investing.com Canada
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Equillium (NASDAQ:EQ) Shares Down 0.9% – What’s Next? - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Equillium (NASDAQ:EQ) Stock Price Down 1.6% – What’s Next? - Defense World
Equillium stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Equillium Announces Board and Audit Committee Changes - TipRanks
Contrasting CSL (OTCMKTS:CSLLY) and Equillium (NASDAQ:EQ) - Defense World
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St
Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com Nigeria
Equillium CFO Jason Keyes sells $7,000 in stock - Investing.com
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - BioSpace
Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks
Equillium to Present at the Stifel Healthcare Conference - The Bakersfield Californian
Equillium to Present Clinical Pipeline Updates at Stifel Healthcare Conference | EQ Stock News - StockTitan
Equillium Inc Azioni (EQ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Equillium Inc Azioni (EQ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Keyes Jason A | Chief Financial Officer |
Nov 14 '24 |
Sale |
0.70 |
10,000 |
7,000 |
47,720 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):